Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

✍ Scribed by Kwonoh Park, Jae-Lyun Lee, Inkeun Park, Seongjoon Park, Yongcheol Ahn, Jin-Hee Ahn, Shin Ahn, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn

• Book ID: 118821620
• Publisher: Springer US
• Year: 2012
• Tongue: English
• Weight: 193 KB
• Volume: 29
• Category: Article
• ISSN: 1357-0560
• DOI: 10.1007/s12032-012-0227-7